Orientbio KRX:002630KOSPI
오리엔트바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Orientbio reported revenue of ₩6.6bn, down 14.2% year on year, and operating profit of ₩50m. Orientbio (오리엔트바이오) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Turnaround Screener
Orientbio quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩6.6bn | -14.2% | ₩50m | ₩4.8bn |
| Q4 2025 | ₩8.6bn | -4.0% | −₩1.6bn | −₩1.9bn |
| Q3 2025 | ₩6.9bn | +3.0% | −₩680m | −₩151m |
| Q2 2025 | ₩7.7bn | +4.0% | −₩1.6bn | −₩2.0bn |
| Q1 2025 derived | ₩6.3bn | -1.0% | −₩583m | −₩4.1bn |
| Q4 2024 | ₩9.0bn | +9.4% | −₩1.7bn | −₩1.3bn |
| Q3 2024 | ₩6.7bn | – | −₩691m | −₩1.1bn |
| Q2 2024 | ₩7.4bn | – | −₩67m | −₩6.8bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Orientbio top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Orientbio news Korean headlines
No articles yet.